Decoy Therapeutics has filed a prospectus with the Securities and Exchange Commission (SEC) for the offering of 3.767M common shares on behalf of selling shareholders. The offering will allow existing common shareholders to sell their stakes in the company. The shares are being offered by the shareholders themselves, and Decoy Therapeutics will not receive any proceeds from the sale.

Offering Details

The prospectus outlines the specifics of the transaction, which involves the sale of common stock. The total number of shares registered for the offering is 3.767M. The filing provides necessary regulatory information for potential investors regarding the nature of the securities being offered.

Key Figures

The filing indicates that the offering is strictly on behalf of the selling shareholders. Decoy Therapeutics is not issuing new shares in this transaction, meaning the company's outstanding share count will not increase as a result of this offering. The prospectus is available for public review on the SEC's website.

Decoy Therapeutics Inc. (NASDAQ: DCOY) shares rose 94.06% to $10.71 after the company announced a $21 million private placement financing with a healthcare investor at $5.91 per share. The financing is structured to support the advancement of its lead asset into clinical trials.

The private placement consists of four components. The upfront portion provides approximately $3.5 million in gross proceeds from the sale of common stock at $5.91 per share. The remaining potential proceeds are milestone-based: a Series A warrant could provide an additional $3.5 million upon filing a Clinical Trial Application in the European Economic Area; a Series B warrant could provide $7.0 million upon receiving approval from the UK’s Medicines and Healthcare products Regulatory Agency to conduct a Phase 2a human challenge trial; and a Series C warrant could provide an additional $7.0 million upon announcing positive data from that Phase 2a trial. All warrants carry an exercise price equal to the deal price of $5.91 per share.

Financing Structure

The closing of the offering is expected to occur on or about June 29, subject to customary closing conditions. Curvature Securities LLC is acting as sole placement agent.